AU6461201A - Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications - Google Patents
Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applicationsInfo
- Publication number
- AU6461201A AU6461201A AU6461201A AU6461201A AU6461201A AU 6461201 A AU6461201 A AU 6461201A AU 6461201 A AU6461201 A AU 6461201A AU 6461201 A AU6461201 A AU 6461201A AU 6461201 A AU6461201 A AU 6461201A
- Authority
- AU
- Australia
- Prior art keywords
- cell
- antibody
- treatment
- combination
- related applications
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21770600P | 2000-07-12 | 2000-07-12 | |
US09/772,938 US20020006404A1 (en) | 1999-11-08 | 2001-01-31 | Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications |
PCT/US2001/015677 WO2002004021A1 (en) | 2000-07-12 | 2001-05-16 | Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications |
Publications (1)
Publication Number | Publication Date |
---|---|
AU6461201A true AU6461201A (en) | 2002-01-21 |
Family
ID=26912176
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU6461201A Pending AU6461201A (en) | 2000-07-12 | 2001-05-16 | Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications |
AU2001264612A Ceased AU2001264612C1 (en) | 1999-11-08 | 2001-05-16 | Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001264612A Ceased AU2001264612C1 (en) | 1999-11-08 | 2001-05-16 | Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP1305045A1 (en) |
JP (1) | JP2004502742A (en) |
KR (2) | KR20030031957A (en) |
CN (1) | CN1446104A (en) |
AU (2) | AU6461201A (en) |
CA (1) | CA2415100A1 (en) |
IL (1) | IL153764A0 (en) |
MX (1) | MXPA03000306A (en) |
NO (1) | NO20030128L (en) |
SG (1) | SG136804A1 (en) |
WO (1) | WO2002004021A1 (en) |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20080039550A (en) | 1999-05-07 | 2008-05-07 | 제넨테크, 인크. | Treatment of autoimmune diseases with antagonists which bind to b cell surface markers |
JP2004512262A (en) * | 2000-06-20 | 2004-04-22 | アイデック ファーマスーティカルズ コーポレイション | Non-radioactive anti-CD20 antibody / radiolabeled anti-CD22 antibody combination |
CN1592645A (en) * | 2000-09-18 | 2005-03-09 | 拜奥根Idec公司 | Combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory anti-body combination |
ATE391174T1 (en) | 2000-10-20 | 2008-04-15 | Chugai Pharmaceutical Co Ltd | MODIFIED TPO AGONIST ANTIBODY |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
CN100574803C (en) * | 2001-01-31 | 2009-12-30 | 拜奥根Idec公司 | The purposes of immunoregulatory antibody in the treatment neoplastic disease |
US20020197256A1 (en) * | 2001-04-02 | 2002-12-26 | Genentech, Inc. | Combination therapy |
AU2003210266A1 (en) * | 2002-02-14 | 2003-09-04 | Bioinvent International Ab | Treatment, diagnosis and imaging of disease |
GB0210121D0 (en) * | 2002-05-02 | 2002-06-12 | Celltech R&D Ltd | Biological products |
CN101928344B (en) | 2002-10-17 | 2014-08-13 | 根马布股份公司 | Human monoclonal antibodies against cd20 |
HU227217B1 (en) | 2002-12-16 | 2010-11-29 | Genentech Inc | Immunoglobulin variants and uses thereof |
JP2004279086A (en) | 2003-03-13 | 2004-10-07 | Konica Minolta Holdings Inc | Radiation image conversion panel and method for manufacturing it |
JPWO2004087763A1 (en) * | 2003-03-31 | 2006-07-27 | 中外製薬株式会社 | Modified antibody against CD22 and use thereof |
MXPA05010778A (en) | 2003-04-09 | 2005-12-12 | Genentech Inc | Therapy of autoimmune disease in a patient with an inadequate response to a tnf-alpha inhibitor. |
KR20060027801A (en) | 2003-06-05 | 2006-03-28 | 제넨테크, 인크. | Combination therapy for b cell disorders |
ES2358427T3 (en) | 2003-10-16 | 2011-05-10 | Micromet Ag | ELEMENTS OF UNION TO CD-3 MULTI-SPECIFIC DEMUNITIES. |
WO2005044307A2 (en) * | 2003-11-04 | 2005-05-19 | Chiron Corporation | Methods of therapy for b cell-related cancers |
US8277810B2 (en) | 2003-11-04 | 2012-10-02 | Novartis Vaccines & Diagnostics, Inc. | Antagonist anti-CD40 antibodies |
RS54450B1 (en) | 2003-11-05 | 2016-06-30 | Roche Glycart Ag | Antigen binding molecules with increased fc receptor binding affinity and effector function |
JP5848861B2 (en) | 2004-04-20 | 2016-01-27 | ジェンマブ エー/エスGenmab A/S | Human monoclonal antibody against CD20 |
MY194883A (en) | 2004-06-04 | 2022-12-21 | Genentech Inc | Method for treating multiple sclerosis |
US8444973B2 (en) | 2005-02-15 | 2013-05-21 | Duke University | Anti-CD19 antibodies and uses in B cell disorders |
HUE025945T2 (en) * | 2005-02-15 | 2016-07-28 | Univ Duke | Anti-cd19 antibodies and uses in oncology |
WO2006106903A1 (en) | 2005-03-31 | 2006-10-12 | Chugai Seiyaku Kabushiki Kaisha | sc(Fv)2 STRUCTURAL ISOMERS |
EP3050963B1 (en) | 2005-03-31 | 2019-09-18 | Chugai Seiyaku Kabushiki Kaisha | Process for production of polypeptide by regulation of assembly |
WO2006114115A1 (en) * | 2005-04-26 | 2006-11-02 | Trion Pharma Gmbh | Combination of antibodies and glucocorticoids for treating cancer |
AU2006256041B2 (en) | 2005-06-10 | 2012-03-29 | Chugai Seiyaku Kabushiki Kaisha | Stabilizer for protein preparation comprising meglumine and use thereof |
US9241994B2 (en) | 2005-06-10 | 2016-01-26 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical compositions containing sc(Fv)2 |
EP2298815B1 (en) | 2005-07-25 | 2015-03-11 | Emergent Product Development Seattle, LLC | B-cell reduction using CD37-specific and CD20-specific binding molecules |
NZ565173A (en) | 2005-07-25 | 2012-01-12 | Emergent Product Dev Seattle | Single dose use of CD20 scFv for rheumatoid arthritis |
AU2006281803B9 (en) | 2005-08-18 | 2013-05-30 | Genmab A/S | Therapy with CD4 binding peptides and radiation |
AU2006308606C1 (en) | 2005-11-01 | 2013-07-25 | Novartis Ag | Uses of anti-CD40 antibodies |
AU2006318539B2 (en) | 2005-11-23 | 2012-09-13 | Genentech, Inc. | Methods and compositions related to B cell assays |
DK2009101T3 (en) | 2006-03-31 | 2018-01-15 | Chugai Pharmaceutical Co Ltd | Antibody modification method for purification of a bispecific antibody |
MEP39508A (en) | 2006-04-21 | 2011-02-10 | Novartis Ag | Antagonist anti-cd40 antibody pharmaceutical compositions |
WO2007146968A2 (en) | 2006-06-12 | 2007-12-21 | Trubion Pharmaceuticals, Inc. | Single-chain multivalent binding proteins with effector function |
KR101643514B1 (en) | 2007-07-09 | 2016-07-27 | 제넨테크, 인크. | Prevention of disulfide bond reduction during recombinant production of polypeptides |
EP2200631A1 (en) | 2007-10-16 | 2010-06-30 | Zymogenetics, Inc. | Combination of blys inhibition and anti-cd 20 agents for treatment of autoimmune disease |
US7914785B2 (en) | 2008-01-02 | 2011-03-29 | Bergen Teknologieverforing As | B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome |
EP2077281A1 (en) | 2008-01-02 | 2009-07-08 | Bergen Teknologioverforing AS | Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome |
NZ603059A (en) | 2008-04-11 | 2014-07-25 | Emergent Product Dev Seattle | Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof |
TW201438738A (en) | 2008-09-16 | 2014-10-16 | Genentech Inc | Methods for treating progressive multiple sclerosis |
WO2010075249A2 (en) | 2008-12-22 | 2010-07-01 | Genentech, Inc. | A method for treating rheumatoid arthritis with b-cell antagonists |
DK2464725T3 (en) | 2009-08-11 | 2020-06-02 | Hoffmann La Roche | Preparation of proteins in glutamine-free cell culture media |
WO2011100403A1 (en) | 2010-02-10 | 2011-08-18 | Immunogen, Inc | Cd20 antibodies and uses thereof |
KR101764572B1 (en) * | 2010-03-12 | 2017-08-03 | 이뮤노젠 아이엔씨 | Cd37-binding molecules and immunoconjugates thereof |
AR083847A1 (en) | 2010-11-15 | 2013-03-27 | Novartis Ag | FC VARIANTS (CONSTANT FRAGMENT) SILENCERS OF ANTI-CD40 ANTIBODIES |
SG11201602261VA (en) | 2013-09-27 | 2016-04-28 | Chugai Pharmaceutical Co Ltd | Method for producing polypeptide heteromultimer |
MA41459A (en) | 2015-02-03 | 2017-12-12 | Als Therapy Development Inst | ANTI-CD40L ANTIBODIES AND METHODS FOR TREATING CD40L ILLNESSES OR DISORDERS |
CA2986437A1 (en) | 2015-06-08 | 2016-12-15 | Debiopharm International, S.A. | Anti-cd37 immunoconjugate and anti-cd20 antibody combinations |
IL302486A (en) | 2015-06-24 | 2023-06-01 | Hoffmann La Roche | Anti-transferrin receptor antibodies with tailored affinity |
KR20180042423A (en) | 2015-08-28 | 2018-04-25 | 데비오팜 인터네셔날 에스 에이 | Antibodies and assays for detection of CD37 |
SG10202002577XA (en) | 2015-09-21 | 2020-04-29 | Aptevo Res & Development Llc | Cd3 binding polypeptides |
CA2997801A1 (en) | 2015-10-02 | 2017-04-06 | F. Hoffmann-La Roche Ag | Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use |
AR106189A1 (en) | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | BIESPECTIFIC ANTIBODIES AGAINST HUMAN A-b AND THE HUMAN TRANSFERRINE RECEIVER AND METHODS OF USE |
KR20180064534A (en) | 2015-11-02 | 2018-06-14 | 바이오아트라, 엘엘씨 | The conditionally active polypeptide |
JP7219005B2 (en) | 2015-12-28 | 2023-02-07 | 中外製薬株式会社 | Methods for Streamlining Purification of Fc Region-Containing Polypeptides |
WO2018083633A1 (en) | 2016-11-02 | 2018-05-11 | Debiopharm International, S.A. | Methods for improving anti-cd37 immunoconjugate therapy |
SG10202111207TA (en) | 2017-05-24 | 2021-11-29 | Als Therapy Development Inst | Therapeutic anti-cd40 ligand antibodies |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3095175B2 (en) * | 1992-11-13 | 2000-10-03 | アイデック ファーマシューティカルズ コーポレイション | Therapeutic use of chimeric and radiolabeled antibodies against human B lymphocyte restricted differentiation antigen for the treatment of B cell lymphoma |
US5736137A (en) * | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
US5595721A (en) * | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
US6001358A (en) * | 1995-11-07 | 1999-12-14 | Idec Pharmaceuticals Corporation | Humanized antibodies to human gp39, compositions containing thereof |
-
2001
- 2001-05-16 WO PCT/US2001/015677 patent/WO2002004021A1/en active IP Right Grant
- 2001-05-16 CA CA002415100A patent/CA2415100A1/en not_active Abandoned
- 2001-05-16 KR KR10-2003-7000429A patent/KR20030031957A/en not_active Application Discontinuation
- 2001-05-16 SG SG200500152-4A patent/SG136804A1/en unknown
- 2001-05-16 JP JP2002508475A patent/JP2004502742A/en not_active Abandoned
- 2001-05-16 MX MXPA03000306A patent/MXPA03000306A/en not_active Application Discontinuation
- 2001-05-16 IL IL15376401A patent/IL153764A0/en unknown
- 2001-05-16 KR KR1020087009742A patent/KR20080039547A/en not_active Application Discontinuation
- 2001-05-16 EP EP01939050A patent/EP1305045A1/en not_active Withdrawn
- 2001-05-16 AU AU6461201A patent/AU6461201A/en active Pending
- 2001-05-16 CN CN01814063A patent/CN1446104A/en active Pending
- 2001-05-16 AU AU2001264612A patent/AU2001264612C1/en not_active Ceased
-
2003
- 2003-01-10 NO NO20030128A patent/NO20030128L/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
IL153764A0 (en) | 2003-07-06 |
WO2002004021A9 (en) | 2003-01-16 |
CA2415100A1 (en) | 2002-01-17 |
KR20030031957A (en) | 2003-04-23 |
MXPA03000306A (en) | 2004-04-05 |
AU2001264612B8 (en) | 2007-02-22 |
KR20080039547A (en) | 2008-05-07 |
EP1305045A1 (en) | 2003-05-02 |
JP2004502742A (en) | 2004-01-29 |
AU2001264612B2 (en) | 2007-02-22 |
NO20030128L (en) | 2003-03-12 |
NO20030128D0 (en) | 2003-01-10 |
AU2001264612C1 (en) | 2007-11-22 |
CN1446104A (en) | 2003-10-01 |
WO2002004021A1 (en) | 2002-01-17 |
SG136804A1 (en) | 2007-11-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL153764A0 (en) | Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications | |
HK1084109A1 (en) | 2-,3-,4-,or 5-substituted-n1-(benzensulfonyl) indoles and their use in therapy 2- | |
AP2002002690A0 (en) | Antibody molecules having specificity for human tumor necrosis factor alphs and use thereof | |
IL157142A0 (en) | Modified antibodies and methods of use | |
GEP20074091B (en) | Cripto blocking antibodies and uses thereof | |
HUP0400284A3 (en) | Recombinant tumor specific antibody and use thereof | |
AU8079901A (en) | Promyostatin peptides and methods of using same | |
EP1404366A4 (en) | Combination therapy of gamma-interferon and b cell specific antibodies | |
GB9927332D0 (en) | Novel antibody and uses thereof | |
GB9806666D0 (en) | Antigen preparation and use | |
AU1334602A (en) | Osteopontin-coated surfaces and methods of use | |
AU2002363938A8 (en) | Methods and use of motoneuronotropic factors | |
PL345208A1 (en) | The induction of antiobiotic proteins and peptides by lait/scd14-protein | |
EP1418194A4 (en) | Modified polyalkyleneimine and methods of using the same | |
EP1302770A4 (en) | Particle-labeled protein and immuno-chromatograph using the same | |
EP1357929A4 (en) | Modulation of immune response and methods based thereon | |
AU2002364612A8 (en) | Methods and materials for modulating enac-beta | |
AU2002227272A1 (en) | Ovarian tumor antigen and methods of use therefor | |
AU7832700A (en) | Ovarian tumor antigen and methods of use therefor | |
GB0003474D0 (en) | Closure of bags and the like | |
HK1072538A1 (en) | Immunoregulatory antibodies and uses thereof | |
AU6886301A (en) | Modulation of fas and fasl expression | |
EP1437367A4 (en) | Antibody and use thereof | |
EP1557430A4 (en) | Antibody and utilization of the same | |
AU141299S (en) | Eating implement |